Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Thyroid Surgery for Graves’ Disease and Graves’ Ophthalmopathy
source: The Cochrane Database of Systematic Reviews
year: 2015
authors: Liu ZW, Masterson L, Fish B, Jani P, Chatterjee K
summary/abstract:Background:
Graves’ disease is an autoimmune disease caused by the production of auto-antibodies against the thyroid-stimulating hormone receptor, which stimulates follicular cell production of thyroid hormone. It is the commonest cause of hyperthyroidism and may cause considerable morbidity with increased risk of cardiovascular and respiratory adverse events. Five per cent of people with Graves’ disease develop moderate to severe Graves’ ophthalmopathy. Thyroid surgery for Graves’ disease commonly falls into one of three categories: 1) total thyroidectomy, which aims to achieve complete macroscopic removal of thyroid tissue; 2) bilateral subtotal thyroidectomy, in which bilateral thyroid remnants are left; and 3) unilateral total and contralateral subtotal thyroidectomy, or the Dunhill procedure.
Recent American Thyroid Association guidelines on treatment of Graves’ hyperthyroidism emphasised the role of surgery as one of the first-line treatments. Total thyroidectomy removes target tissue for the thyroid-stimulating hormone receptor antibody. It controls hyperthyroidism at the cost of lifelong thyroxine replacement. Subtotal thyroidectomy leaves a thyroid remnant and may be less likely to lead to complications, however a higher rate of recurrent hyperthyroidism is expected and revision surgery would be challenging. The choice of the thyroidectomy technique is currently largely a matter of surgeon preference, and a systematic review of the evidence base is required to determine which option offers the best outcomes for patients.
organization: Whipps Cross University Hospital, UKDOI: 10.1002/14651858.CD010576.pub2
read more full text
myBinderRelated Content
-
Mycophenolate Plus Methylprednisolone Versus Methylprednisolone Alone in Active, Moderate-to-Severe Graves’ Or...Background: European guidelines recomme...
-
Management of Graves’ Disease: A ReviewImportance: Graves disease is the most ...
-
Casey Eye Institute – Thyroid Eye Disease CenterAs part of Oregon Health & Science U...
-
New Data from Phase 3 Teprotumumab Trial Shows Dramatic Reduction in Proptosis, or Eye Bulging, the Main Cause of Mo...Horizon Pharma plc today announced that ...
-
Relation Between Therapy for Hyperthyroidism and the Course of Graves’ OphthalmopathyBackground: The chief clinical characte...
-
Grading Severity and Activity in Thyroid Eye DiseasePurpose: Thyroid eye disease (TED) is a...
-
Horizon Pharma plc Announces Phase 3 Confirmatory Trial Evaluating Teprotumumab (OPTIC) for the Treatment of Active ...Horizon Pharma plc today announced topli...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Facebook
Google